Physician profile
Ashwin Agarwal
NPI 1760844138
$1,116.10
in general payments reported to CMS, 2019-2025
15 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2020: $39.80 · 2021: $170 · 2022: $137 · 2023: $332 · 2024: $240 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.60 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $193.95 | 2021-2025 | Skyrizi |
| Amgen INC. | $181.60 | 2021-2025 | Otezla, Otezla |
| Allergan, INC. | $122.33 | 2019-2020 | |
| Lilly USA, LLC | $118.61 | 2021-2024 | Taltz, Olumiant |
| Pfizer INC. | $107.82 | 2023-2024 | |
| Galderma Laboratories, L.P. | $87.90 | 2020-2023 | |
| Janssen Biotech, INC. | $72.48 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $60.94 | 2023 | Sotyktu |
| Incyte Corporation | $38.36 | 2022-2023 | Opzelura |
| Ucb, INC. | $34.81 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $25.11 | 2025 | Dupixent |
| Genzyme Corporation | $23.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.30 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.05 | 2023 | Absorica Ld, Winlevi |
| Bayer Healthcare Pharmaceuticals INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.